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Abstract
Esophageal cancer (EC) affects men far more commonly than women. 
Numerous epidemiological studies have suggested that the hormonal milieu may 
play a role in this gender bias. However, there is little known about circulating 
sex hormone levels in relation to the risk of EC development. In this chapter, the 
correlation between circulating sex hormone levels and mRNA expression of 
estrogen receptors (ER) in normal esophageal mucosal samples and EC biopsies 
from patients with potentially resectable EC is studied. Moreover, the association of 
serum sex hormones levels with and clinico-pathological features of EC is analysed.
Keywords: esophageal, cancer, squamous, adenocarcinoma, sex hormones, estrogen, 
testosterone, estradiol
1. Introduction
Sex steroid hormones are essential for normal reproductive health in both 
sexes. Estrogens in women and androgens in men are crucial for development of 
sexual organs and regulation of gametogenesis. They also play vital roles in regulat-
ing physiological functions of other non-target tissues and organs. For instance, 
estrogens are involved in the maintenance of bone mass, regulation of lipoprotein 
synthesis, prevention of urogenital atrophy, regulation of insulin responsiveness, 
and maintenance of cognitive function.
Sex steroids hormones are also linked with development, progression, or 
treatment of several cancers that include breast, uterine, prostate, and testicular 
cancer [1].
Indeed, the correlation between endogenous sex steroid hormones and the risk 
of developing breast cancer is well described in the literature. Besides, the use of 
anti-estrogenic therapy is associated with better local control and survival outcome 
in patients with breast cancer [2].
Esophageal cancer (EC) is the eighth most common cancer and the sixth most 
common cause of cancer mortality worldwide [3]. Despite developments in treat-
ment modalities, estimated overall five-year survival rate for patients with EC is still 
poor, one of the characteristic features of EC, especially esophageal adenocarcinoma 
(EAC) is a persistence gender bias over several decades, in all races and across the 
world [3–5]. Although EC is not a hormone-dependant tumour, several epidemiologi-
cal studies suggested that female sex hormones may have a protective role against 
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the development of this aggressive malignancy [6, 7]. There is mounting evidence 
that the male predominance associated with oesophageal cancer is age dependent. 
The gender ratio is at its highest at a younger age, whereas the incidence difference 
between older men and women is smaller afterwards [8, 9]. This gender ratio seems to 
have been consistent during the last decades, despite the increasing incidence in EAC.
Several epidemiological studies investigated the possible association between 
the endogenous and exogenous sex hormonal exposure and EC. Lindblad et al. 
suggested that the use of HRT was not associated with a reduced risk of EC of 
any histological type [10]. Similarly, two recent studies examined the association 
between the use of HRT and the risk of EAC and squamous cell carcinoma (ESCC) 
in postmenopausal women [11, 12]. Freedman et al. found that the use of HRT was 
significantly associated with lower risk of ESCC and with a non-significant lower 
risk of EAC. Moreover, older age at menopause was inversely associated with ESCC. 
This risk reduction was more evident in women with intact uteri and who received 
estrogen and progestin containing HRT. Therefore, it was suggested that higher 
estrogen and progesterone levels may be related inversely to EC and in this way 
help explain the lower incidence rates in women compared to men [11]. In contrast, 
another study of 161,086 postmenopausal women involved in the Women’s Health 
Initiative (WHI), showed that the risk of ESCC was only lower among HRT users 
with a decreased risk mainly among current users of estrogen and progestin con-
taining HRT. No association was observed between the use of HRT and the risk of 
EAC. Also, no other reproductive or hormonal factors were significantly associated 
with the risk of either ESCC or EAC [12].
A nested case–control study within a prospective UK cohort and meta-analysis 
found that women prescribed HRT had a reduced risk of OC (adjusted RR for 
HRT versus no HRT prescriptions, 0.68, 95% CI 0.53–0.88; p < 0.004) [13]. There 
were no significant differences in cancer risk by HRT type, estimated duration 
of HRT use or between past and current users [13]. Recently, the Million Women 
Study (MWS) by Green et al examined risk of esophageal and gastric cancers in 
relation to reproductive factors in a large UK cohort [14]. They have shown that 
risks of both esophageal and gastric cancers were higher in postmenopausal than in 
pre- or peri-menopausal women, and, among postmenopausal women, risks were 
higher the younger the women were at menopause [14]. In contrast to some studies 
where no association of childbearing on the risk of AEC was identified [15], the 
MWS demonstrated that the association between parity and risk of EC was more 
significant for ESCC than for EAC and age at menarche was significantly associated 
with EAC but not ESCC [14]. Green et al therefore suggested that the reduced risks 
associated with menopausal status and with hormone therapy use are consistent 
with a hypothesis that exposure to estrogens reduces the risk of EC [14].
On the other hand, in a large population-based cohort of 87, 323 postmenopausal 
women with breast cancer, the potential effects of tamoxifen (Selective ER modulator 
mostly acts as an anti-estrogen) used for breast cancer treatment was evaluated. In this 
study, there was no increase in the risk of developing EC in breast cancer patients who 
received adjuvant tamoxifen treatment in comparison to the control group [16, 17]. 
However, a different large population-based study of 138,885 women (by Chandanos et 
al.) suggested a 60% risk increase of EAC among the exposed group but did not achieve 
statistical significance. In contrast, there was an increased risk of ESCC and lung cancer 
observed only in the unexposed cohort, indicating that the confounding factor of 
smoking might explain the increased incidence during the unexposed period [18].
Interestingly, a dose-dependent risk reduction in EC by breastfeeding was sug-
gested [19]. In a recent study, based on pooled data from several large case–control 
studies, endogenous reproductive factors and exogenous factors were evaluated 
in women. Breastfeeding was associated dose-dependently with a reduced risk of 
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EAC, while parity, menstruation, history of pregnancy, use of oral contraceptives or 
of HRT were not associated with the risk of developing this tumour [20, 21].
In a cohort of patients with prostate cancer, a reduced risk of EAC but not of 
ESCC was noted. Hence, it was suggested that a diagnosis of prostate cancer may be 
linked with aetiological factors that are negatively associated with EAC, or anti-
androgen therapy may influence the development of EAC [22]. In contrast, estrogen 
exposure in a national cohort of men with prostate cancer did not show any reduced 
risk of a second AEC [23]. Despite these efforts to explain the relation between 
female reproductive factors and risk of development of EC, the results are rather 
unclear and contradict each other. This could be partially explained by the fact that 
the number of women with EC included in those studies was relatively small, which 
could have the affected potential significance of the results [24].
Recently, it has suggested that the ER system is involved in EC progression and 
thus may provide a novel target for the treatment of EC [25]. However, there is little 
known about sex hormones levels in relation to the risk of EC development. In this 
study we aimed to:
1. Describe sex hormones profiles in a cohort of patients with established OC.
2. Identify whether there is any correlation between circulating sex hormone 
levels and mRNA expression of estrogen receptors (ER) in normal esophageal 
mucosal samples and EC biopsies.
3. Analyse the correlation between circulating sex hormone levels and clinic-
pathological features of EC.
2. Material and methods
2.1 Patient cohort
Joint ethical approval for the research protocol was acquired from the Derbyshire 
Research Ethics Committee and Derbyshire Hospitals Research and Development 
office. Written, informed consent was obtained from all patients included in this study. 
EC samples and matched normal tissue taken from adjacent macroscopic mucosa from 
the same patient were collected from resected EC specimens of 34 patients [EAC: n = 
28; ESCC: n= 6] who underwent esophagectomy. Normal samples were microscopi-
cally examined by a consultant pathologist to confirm normal features.
2.2 mRNA analysis by qRT-PCR
Total RNA was extracted from tissue samples (30 mg), ground in liquid N2 with 
a pestle and mortar and from cell lines (104 cells) using the RNeasy Mini kit method 
(QIAGEN, UK) as per manufacturer’s protocol. 300 ng of total RNA was reverse tran-
scribed with (+RT) or without (-RT) reverse transcriptase (RT) using the high-capac-
ity cDNA reverse transcription kit (Life Technologies, Paisley, UK). 2 μl of cDNA 
were amplified by real time PCR with commercially available TaqMan assays (Life 
Technologies, Paisley, UK) for ESR1 (Hs00174860_m1), ESR2 (Hs01100353_m1), and 
the reference genes GAPDH (Hs02758991_g1), PGK1 (Hs00943178_g1), and ACTB 
(Hs01060665_g1) in a Chromo 4 thermal cycler (Bio-Rad Laboratories LTD, Hemel 
Hempstead, UK). Expression of ESR1 and ESR2 was quantified relative to the geo-
metric mean of three reference genes and reported as relative to max using the GenEX 




Immunohistochemistry (IHC) slides were prepared in the Histopathology 
Department at the Royal Derby Hospital. Normal mucosa and EC samples were 
stained using ERα and ERβ antibodies (NCL-L-ER-6F11 and 6007907, respectively, 
Novacastra, Newcastle, UK). ERα and ERβ positive breast cancer samples were 
used as positive controls. The ‘H-score method was used to measure the strength 
of ER-staining in normal esophageal mucosa and matched tumour samples [27]. 
Positive staining was defined as an H-score ≥ 10 in this study.
2.4 Blood samples
Blood samples were collected from 34 patients with histologically proven EC. 
Once the patient was anaesthetised, 10 ml of central venous blood was taken using 
gold-top Vacutainer Serum Separation Tubes (BD Vacutainer® SST™). Blood 
samples were immediately transported to the Clinical Chemistry laboratory in Royal 
Derby Hospital for analysis. Fasting serum level of testosterone, luteinizing hormone 
(LH), follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), 
17-β oestradiol (E2) were measured using ElectroChemiLuminescence ImmunoAssay 
(ECLIA, Roche) and as per manufacturer’s protocols. Elecsys and Cobas e immunoas-
say 411 analyzer was used for running of ECLIA (Roche-diagnostic, USA). The free 
androgen index (FAI) was calculated as the total testosterone to SHBG ratio [28].
2.5 Statistical analysis
For qRT-PCR on primary tissues, the two-tailed Wilcoxon signed rank test was 
used for matched cases while the two-tailed Mann-Whitney U test was used for 
non-matched variables. Either the two-tailed Mann-Whitney U test or Kruskal-
Wallis test, as appropriate, was used to establish relationships between hormone 
levels, ER mRNA and clinico-pathological features. Correlation coefficient (r) was 
calculated using two-tail Spearman correlation. Statistical differences were calcu-
lated using SPSS Statistics® for Windows™ v21 software from IBM SPSS Statistics 
(Feltham, UK) and GraphPad Prism® v6 (La Jolla, CA, USA). A value of p ≤ 0.05 
was considered as statistically significant.
3. Results
3.1 Clinico-pathological characteristics of recruited patients
The clinico-pathological characteristics of EC patients included in the analysis are 
summarised in Table 1. Median age was 65 years (range, 30 – 79 years). There were 
28 males and 6 females with male-to-female ratio of 5.7:1. Of those 34 patients, 28 
patients had EAC and 6 patients had ESCC. One-year disease specific survival was 
approximately 73.5%. Twenty-five (74%) patients received neoadjuvant therapy.
3.2 Sex hormones profiles
The median (Inter quartile range) (IQR) of the serum sex hormones levels (34 
patients) against their corresponding laboratory reference ranges (Derby Hospital 
biochemistry department) is summarised in Table 2. Median serum levels of FSH 
and LH hormone were higher than normal. However, the median of serum levels of 
E2, progesterone, testosterone, and SHBG were within the normal ranges Table 2.
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In a gender-based analysis, there were significant higher median (IQR) levels of 
LH and FSH in female patients compared to LH and FSH levels in male patients. In 
contrast, women had significantly lower median levels E2, testosterone compared to 
men. There was no significant difference in serum levels of progesterone and SHBG 
between men and women (Table 3).
3.3  Correlation between serum sex hormones level and estrogen receptor 
expression
The results of correlation between serum sex hormones and ERα and ERβ 
expression at mRNA are summarised in Tables 4 and 5. There was no significant 
correlation between the expression of ERα or ERβ mRNA in normal mucosa or 
tumour samples and serum level of LH, FSH, E2, Testosterone, FAI, or SHBG. 
In analysis of the correlation of hormones levels with estrogen receptors expres-
sion in both genders, we found that there was significant inverse correlation 
between testosterone level and ERβ mRNA expression in normal mucosa from 
male patients (r = - 0.41, p = 0.03) (Table 6). In female patients, there was 
significant inverse correlation between progesterone level and ERα mRNA 
expression in EC samples (r = - 0.87, p = 0.04) level (Table 7). No correlation 
was demonstrated between the levels of rest of sex hormones and ERs expres-
sion in either gender (Tables 6 and 7).
Patients recruited 34
Median age (years) 65 (range, 30-79)
One-year disease-specific survival 73.5%
Gender Male 28 (83%)
Female 6 (17%)
Histology EAC 28 (76%)
ESCC 6 (24%)
Tumour depth (T-stage) T1 8 (24%)
T2 3 (9%)
T3 23 (67%)
Nodal involvement No (N0) 15 (44%)
Yes (N1) 19 (56%)
Tumor differentiation Moderate 25 (74%)
Poor 9 (26%)
Vascular invasion No 21(62%)
Yes 13 (38%)
Barrett’s Metaplasia No 13 (46%)
Yes 15 (54%)
Circumferential resection margin Not involved 23 (68%)
Involved 11 (32%)






Hormone (reference range) Median (IQR) of serum level
Male (n = 28) Female (n = 6) p value*
LH (1.7 – 8.6 IU/L) 9.5 (6.5 – 12) IU/L 33.5 (21 – 45.5) IU/L 0.004
FSH (1.5 – 12.4 IU/L) 13 (7.8 - 23) IU/L 62 (40 – 90) IU/L 0.001
E2 (28 – 167 pmol/L) 78 (59 – 98) pmol/L 50 (35 – 50) pmol/L 0.002
Progesterone (0.7 – 4.3 nmol/L) 1.2 (0.8 – 2.4) nmol/L 0.9 (0.8 – 1.5) nmol/L 0.51
Testosterone (8.3 – 27.8 nmol/L) 14 (8 – 20) nmol/L 0.5 (0.3 – 1.1) nmol/L 0.0001
SHBG (14.5 – 48.4 nmol/L) 54 (32 – 65) nmol/L 40 (28.5 – 89) nmol/L 0.84
FAI (34 – 106 %) 21.5% (16% – 35%) 1% (0.5% – 3%) 0.001
LH, luteinizing hormone; FSH, follicular stimulating hormone; E2, 17β-Oestradiol; SHBG, serum hormone binding 
globulin; FHI, free androgen index.
*Calculated using two-tail Mann Whitney U test.
Table 3. 
Gender-based comparison of serum sex hormones levels in patients with EC.
Hormone (reference range) Median (IQR) of serum level
LH (1.7 – 8.6 IU/L) 9.9 (7, 17) IU/L
FSH (1.5 – 12.4 IU/L) 17 (9.6, 28) IU/L
E2 (28 – 167 pmol/L) 73 (50, 95) pmol/L
Progesterone (0.7 – 4.3 nmol/L) 1.1 (0.5, 1.15) nmol/L
Testosterone (8.3 – 27.8 nmol/L) 12 (6.5, 16.5) nmol/L
SHBG (14.5 – 48.4 nmol/L) 52 (32, 68) nmol/L
FAI (34 – 106 %) 20.5% (12%, 31%)
LH, luteinizing hormone; FSH, follicular stimulating hormone; E2, 17β-Oestradiol; SHBG, serum hormone binding 
globulin; FHI, free androgen index.
Table 2. 
The median (IQR) of serum sex hormones levels of patients with EC (n = 34).
Hormone ESR1 (ERα) mRNA expression
Normal mucosa Tumour
r p-value* r p-value*
LH 0.08 0.69 0.16 0.41
FSH - 0.16 0.38 0.04 0.83
E2 0.11 0.55 0.03 0.99
Progesterone 0.2 0.26 0.22 0.2
Testosterone 0.10 0.56 0.10 0.57
SHBG - 0.2 0.32 0.08 0.68
FAI 0.31 0.11 - 0.08 0.7
LH, luteinizing hormone; FSH, follicle stimulating hormone; E2, 17β-Oestradiol; SHBG, serum hormone binding 
globulin; FHI, free androgen index; r, the correlation coefficient.
*Calculated using two-tail Spearman correlation.
Table 4. 
Correlation between serum sex hormones levels and ERα mRNA expression.
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Hormone ESR2 (ERβ) mRNA expression
Normal mucosa Tumour
r p-value* r p-value*
LH - 0.22 0.24 - 0.01 0.94
FSH 0.08 0.67 - 0.03 0.85
E2 0.02 0.92 - 0.16 0.38
Progesterone 0.08 0.66 - 0.18 0.33
Testosterone - 0.03 0.08 - 0.14 0.43
SHBG 0.07 0.7 0 1
FAI - 0.14 0.49 - 0.25 0.21
LH, luteinizing hormone; FSH, follicle stimulating hormone; E2, 17β-Oestradiol; SHBG, serum hormone binding 
globulin; FHI, free androgen index; r, the correlation coefficient.
*Calculated using two-tail Spearman correlation.
Table 5. 
Correlation between serum sex hormones levels and ERβ mRNA expression.
Hormone ESR1 (ERα) mRNA expression ESR1 (ERβ) mRNA expression
Normal mucosa Tumour Normal mucosa Tumour
r p-value* r p-value* r p-value* r p-value*
LH 0.13 0.53 0.19 0.36 - 0.26 0.21 - 0.06 0.77
FSH - 0.13 0.52 - 0.04 0.85 0.07 0.72 - 0.17 0.41
E2 0.07 0.73 0.08 0.69 0.05 0.80 - 0.07 0.73
Progesterone - 0.13 0.54 0.08 0.71 - 0.27 0.19 0.10 0.62
Testosterone 0.09 0.64 0.26 0.19 - 0.41 0.03 - 0.03 0.88
SHBG 0.13 0.52 0.08 0.69 - 0.01 0.99 - 0.07 0.74
FAI 0.35 0.11 0.09 0.68 - 0.22 0.36 - 0.14 0.53
LH, luteinizing hormone; FSH, follicle stimulating hormone; E2, 17β-Oestradiol; SHBG, serum hormone binding 
globulin; FHI, free androgen index; r, the correlation coefficient.
*Calculated using two-tail Spearman correlation.
Table 6. 
Correlation between serum sex hormones levels and estrogen receptors mRNA expression in male  
patients (n = 28).
Hormone ESR1 (ERα) mRNA expression ESR1 (ERβ) mRNA expression
Normal mucosa Tumour Normal mucosa Tumour
r p-value* r p-value* r p-value* r p-value*
LH - 0.80 0.20 - 0.80 0.20 - 0.40 0.60 0.40 0.60
FSH - 0.36 0.55 -0.22 0.74 0.10 0.87 0.31 0.61
E2 0.71 0.18 0.71 0.18 - 0.35 0.56 0.35 0.56
Progesterone - 0.62 0.27 - 0.87 0.04 - 0.21 0.74 0.36 0.55
Testosterone 0 1.0 - 0.20 0.75 0.60 0.29 - 0.70 0.19
SHBG - 0.56 0.32 - 0.15 0.81 0.46 0.43 - 0.21 0.74
FAI 0.37 0.54 0 1.00 0 1.00 - 0.16 0.80
LH, luteinizing hormone; FSH, follicle stimulating hormone; E2, 17β-Oestradiol; SHBG, serum hormone binding 
globulin; FHI, free androgen index; r, the correlation coefficient.
*Calculated using two-tail Spearman correlation.
Table 7. 
Correlation between serum sex hormones levels and estrogen receptors mRNA expression in female  






T-Stage LN-stage Grade VI BM CRM
LH r 0.04 - 0.08 0.21 0.18 0.04 - 0.01 - 0.06
p-value* 0.87 0.71 0.30 0.39 0.83 0.98 0.78
FSH r - 0.03 - 0.18 0.25 - 0.13 - 0.28 - 0.02 - 0.16
p-value* 0.88 0.36 0.21 0.61 0.16 0.943 0.50
E2 r - 0.27 - 0.125 0.12 0 0.10 -.018 0.02
p-value* 0.17 0.53 0.54 1.00 0.61 0.93 0.92
Progesterone r - 0.25 - 0.21 0.39 0.27 - 0.16 - 0.06 - 0.25
p-value* 0.28 0.32 0.05 0.19 0.46 0.77 0.23
Testosterone r 0.21 0.18 0.15 0.12 0.06 - 0.04 0.05
p-value* 0.28 0.35 0.44 0.53 0.78 0.86 0.81
SHBG r 0.24 0.13 0.08 0.13 - 0.09 - 0.17 - 0.01
p-value* 0.24 0.51 0.69 0.53 0.65 0.39 0.96
FAI r - 0.17 - 0.08 - 0.24 - 0.22 - 0.15 0.20 - 0.50
p-value* 0.61 0.72 0.29 0.33 0.61 0.37 0.02
LH, luteinizing hormone; FSH, follicle stimulating hormone; E2, 17β-Oestradiol; SHBG, serum hormone binding 
globulin; FHI, free androgen index; T-stage, tumour depth; LN-stage, lymph node involvement; VI, vascular 
invasion; BM, barrett’s metaplasia; CRM, circumferential resection margin; r, the correlation coefficient.
*Calculated using two-tail Spearman correlation.
Table 9. 
Correlation between serum sex hormones levels and pathological features in male patients (n = 28).
Hormone Disease specific one-year survival
Males Females
LH R - 0.33 R 0.26
p-value* 0.10 p-value* 0.74
FSH R 0.12 r 0.36
p-value* 0.56 p-value* 0.55
E2 R 0.32 r 1.000**
p-value* 0.10 p-value* < 0.0001
Progesterone R 0.16 R 0.36
p-value* 0.46 p-value* 0.55
Testosterone R 0.19 R 0.35
p-value* 0.37 p-value* 0.56
SHBG R 0.21 R 0.36
p-value* 0.29 p-value* 0.55
FAI r 0.21 r 0.19
p-value* 0.35 p-value* 0.76
LH, luteinizing hormone; FSH, follicle stimulating hormone; E2, 17β-Oestradiol; SHBG, serum hormone binding 
globulin; FHI, free androgen index; r, the correlation coefficient.
*Calculated using two-tail Spearman correlation.
Table 8. 
Correlation of serum sex hormones level & 1-year disease specific survival.
9
Serum Sex Hormone Profiles in Potentially Resectable Esophageal Cancer
DOI: http://dx.doi.org/10.5772/intechopen.95030
3.4  Correlation between serum sex hormones levels and clinico-pathological 
features
Gender-based analysis of correlation between serum hormones levels and 
survival outcome at one year and pathological features after intended curative 
resection was performed using two-tail Spearman test. There was highly significant 
positive correlation between 1-year disease survival outcome and serum E2 level in 
female patients (r = 1, p < 0.0001) (Table 8). However, no significant association 
was determined between sex hormones levels and 1-year disease specific survival in 
male patients (Table 7).
No correlation was demonstrated between serum hormonal levels and patho-
logical features of EC from either male or female patients (Tables 9 and 10).
4. Discussion
In this study, we investigated sex steroid hormones profiles in patients with 
established EC. Our results demonstrated that there was no correlation between 
serum level of LH, FHS, E2, SHBG, or FAI and ER expression in normal esophageal 
mucosa or EC from both genders. Whilst 1-year disease survival is significantly cor-
related with high E2 level in female patients, no significant correlation is identified 
between survival outcome and sex hormones level in male patients.
The disparity in the incidence of EC between males and females has always 
raised the question regarding the role of sex hormones and sex EC in esophageal 




T-Stage LN-stage Grade VI BM CRM
LH r - 0.78 - 0.78 0.78 - 0.26 0.78 - 0.78 0
p-value* 0.23 0.23 0.23 0.74 0.23 0.23 1.00
FSH r - 0.18 - 0.74 0.74 0.18 0 -.725 - 0.15
p-value* 0.77 0.15 0.15 0.77 1.00 0.17 0.81
E2 r - 0.25 - 0.41 0.41 0.25 - 0.41 0.25 - 0.61
p-value* 0.69 0.50 0.50 0.69 0.50 0.69 0.27
Progesterone r - 0.73 - 0.44 0.44 - 0.18 0.74 - 0.73 0.15
p-value* 0.17 0.45 0.45 0.77 0.15 0.17 0.81
Testosterone r 0 0.58 - 0.58 0.71 0.87 - 0.35 0.87
p-value* 1.00 0.31 0.31 0.18 0.06 0.56 0.06
SHBG r 0.73 0 0 - 0.18 - 0.44 - 0.18 0.15
p-value* 0.17 1.00 1.00 0.77 0.45 0.77 0.81
FAI R 0.56 0.15 - 0.15 0.56 0.76 - 0.19 0.30
p-value* 0.33 0.81 0.81 0.33 0.14 0.76 0.62
LH, luteinizing hormone; FSH, follicle stimulating hormone; E2, 17β-Oestradiol; SHBG, serum hormone binding 
globulin; FHI, free androgen index; T-stage, tumour depth; LN-stage, lymph node involvement; VI, vascular 
invasion; BM, barrett’s metaplasia; CRM, circumferential resection margin; r, the correlation coefficient.
*Calculated using two-tail Spearman correlation.
Table 10. 
Correlation between serum sex hormones levels and pathological features in female patients (n = 6).
Reproductive Hormones
10
effect of E2 and testosterone on the growth of newly established cancer cell lines of 
ESCC origin, which expressed both ER and androgen receptor (AR). They found 
that the growth rate of the cell lines was inhibited by estrogen and enhanced by 
testosterone [29]. In a similar way, Utsumi et al. suggested that the presence of ER 
arbitrates the inhibitory effect of estrogen when it was noted that the growth of 
ER positive transplanted tumour was significantly greater in male than it was in 
female nude mice. Such a difference was not observed for ER negative tumour. Also, 
the growth rate of ER positive tumours was enhanced in oophorectomised female 
mice and significantly suppressed with a physiological dose of E2 compared to ER 
negative cancer [30, 31]. Likewise, Ueo et al studied sex hormone dependency and 
hormone responsiveness on both ER positive (KSE-1) and ER negative (KSE-2) 
ESCC cell lines transplanted in male and female nude mice. They found that the 
administration of E2 significantly inhibited the growth of KSE-1 tumours in both 
males and females in conjunction with an increase in E2 levels. No similar influ-
ence on KSE-2 growth was identified. Therefore, they suggested that the growth of 
human EC cells with sex hormone receptor is influenced by circulating hormone 
levels and can be manipulated by systemic E2 administration [32].
EAC often expresses ER, which suggests a possible biological involvement of 
steroid hormones. Wang et al. suggested that ER and their signalling could have a 
role in EC development when he found that 43.75% (21/48) and 20.83% (10/48) of 
EC cases were positive for ER and progesterone receptor (PR) respectively, while 
these receptors were negative in esophageal tissues taken from normal subjects [33]. 
Similarly, Tiffin et al suggested that the role of ER may warrant further investiga-
tion when they identified mild to moderate ER staining in most of their esophageal 
tissue samples. However, the author did not discriminate between the ER subtypes 
detected [34]. Interestingly, Nozoe et al found that ERα expression was signifi-
cantly higher in male patients with ESCC in comparison to females. Also, a positive 
expression of ERα plus negative expression of ERβ was found to be an unfavourable 
independent prognostic indicator in patients with ESCC. Therefore, they suggested 
that hormonal therapy using estrogen may have a role in improving the outcome in 
this type of cancer and its possible anti-tumour effect requires more in depth both 
laboratory and clinical based investigations [35]. Akgun et al. studied the expression 
of ERβ in Barrett’s metaplasia and associated EAC. They concluded that all EAC and 
most precursor lesions, Barrett's metaplasia with or without dysplasia, express ERβ 
in a significantly high percentage of the cells. These findings raise the possibility that 
EAC may benefit from treatment and/or chemoprevention by SERM [36]. Likewise, 
Liu et al. found that ERβ1, ERβ2, ERβ3 and ERβ5 are overexpressed in EAC com-
pared to its precursor lesion Barrett’s metaplasia negative for dysplasia, suggesting 
a significant biological role [37]. In contrast, Kalayarasan et al. studied the expres-
sion of ERα and ERβ as well as Progesterone Receptors (PR) in both tumour tissue 
and adjacent normal mucosa samples of 45 cases of EC (ESCC = 30 cases, EAC= 
15 cases). They found neither tumours nor normal mucosa expressed ERα or PR. 
However, all cases of EAC, irrespective of their stage/grade, were strongly positive 
for ERβ and the intensity of staining in tumours was significantly higher than in 
normal adjacent mucosa. Therefore, they suggested that estrogen may have an effect 
on the growth of EAC and this effect may be mediated by ERβ [38]. Despite numer-
ous studies assessing the role of sex hormones in AEC development, the findings are 
still featured by some inconsistency. It seems therefore important that the molecular 
mechanisms of ER in esophageal carcinogenesis are further clarified.
Recently, Zuguchi et al found that there is increased nuclear ERβ reactivity in 
human ESCC in comparison to matched normal mucosa [39]. Moreover, increased 
ERβ expression seems to have unfavourable correlation to the histo-pathological 
stage of the disease [39]. Therefore, they concluded that EC is an estrogen dependant 
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malignancy and ERβ might provide an additional therapeutic target for treatment 
of ESCC [39]. Another study by Sukocheva et al demonstrated that tamoxifen and 
raloxifen inhibited the growth of esophageal AC cell lines proliferation by inducing 
apoptosis and cell cycle arrest [40]. However, the study did not differentiate between 
the role of each receptor, especially when we know for fact that SERMs have different 
agonist and antagonist function of ER in different body tissues.
Several studies demonstrated that women undergoing curative EC resection 
have better long term survival outcome compared to men [6, 7]. In a case control 
study, Wang et al, found that there was a low serum E2 level from healthy controls 
from an area with a high incidence of ESCC compared to counterparts from a 
low incidence area in China [41]. Hence, they suggested that the discrepancy in 
incidence of ESCC may be explained by the lack of a protective E2 effect [41]. In 
another study, Petrick JL et al identified a high ratio of androgens to estrogens – 
particularly testosterone:estradiol ratio – was more common in EAC patients than 
controls, including after restriction to cases without weight loss in the previous 5 
years [42]. The lack of association between circulating E2 and ER expression in this 
study may reflect the theoretical possibility that ER expression is influenced more 
by intra-tumor E2 rather than circulating hormone concentrations [43, 44]. For 
instance, Recchione et el found that E2 level in breast cancer samples is significantly 
higher compared to serum level of E2. Similarly, in a comparison of blood and 
breast cancer tissue concentrations sex steroids by Secreto et al showed that there 
was significantly higher level of E2 in the tumours than in the blood [45].
Recently, Xie, S-H et al found that an increased disease-specific mortality with 
lower SHBG levels and higher FSH levels in male EAC patients without surgical 
treatment. No clear associations were observed for dehydroepiandrosterone sul-
phate, LH, prolactin, testosterone, 17-OH-progesterone, progesterone, E2, andro-
stenedione, testosterone:estradiol ratio or free testosterone index [46]. In our study, 
there was no correlation between sex hormones level and pathological features. 
However, we found higher serum E2 level had significant positive correlation with 
1-year disease specific survival in women. This may indicate that E2 may play anti-
proliferative effect and in turn reduce the risk of developing distant micro metasta-
ses. For example, high dose estrogens, like diethylstilbestrol found to paradoxically 
inhibit breast cancer growth by activation of Fas/FasL apoptotic pathway [47]. In 
another in vitro study, Al-Khyatt et al found that ERs antagonists induced apoptosis 
in EC cell lines proliferation. Thus, they concluded that their findings may indicate 
that the ER system is involved in OC progression and thus may provide a novel 
target for the treatment of OC [25].
In a study by Awan et al [48], a raised testosterone level had a positive correla-
tion with the presence of EC compared to control group. Furthermore, serum tes-
tosterone levels decreased after surgical resection of the tumour [48]. In this study 
it was demonstrated that testosterone had an inverse correlation with ERβ mRNA 
expression in normal mucosa from male patients. Several studies investigated the 
role of androgens in the pathogenesis of estrogen-dependant cancers like breast 
cancer [49]. Nevertheless, the significance of cross-talk between androgens and ER 
in EC is not clear and warrants further investigation [50].
The number of patients used in this study is relatively small, especially female 
patients. This could be the reason behind the lack of any association between serum 
sex hormones and ER expression or pathological features. Another limitation is 
there was no matched healthy control. The serum sex hormones levels of healthy 
controls could have been used for comparison as well as studying the correlation 
between hormones levels and risk factors profiles for EC.
In summary, in this study, there was no association between sex hormones 
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Interestingly, survival outcome was better in women with increased serum level 
of E2. Current published evidence supports that sex hormones may play a role in 
esophageal carcinogenesis. Hence, future research work may include a population-
based study looking into the correlation of sex hormones and risk factors profiles 
for EC in healthy volunteers and patients is required. Likewise, a well-designed 
in vivo study to address the potential therapeutic role of ERα and ERβ in treatment 
of EC is warranted.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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